Bois Frédéric, Noirot Camille, Dietemann Sébastien, Mainta Ismini C, Zilli Thomas, Garibotto Valentina, Walter Martin A
Division of Nuclear Medicine, Diagnostic Department, University Hospital of Geneva Geneva, Switzerland.
Division of Radiation Oncology, Oncology Department, University Hospital of Geneva Geneva, Switzerland.
Am J Nucl Med Mol Imaging. 2020 Dec 15;10(6):349-374. eCollection 2020.
Imaging of the prostate-specific membrane antigen (PSMA) has become an important tool for managing patients with recurrent prostate cancer, and one of the most frequently employed radiopharmaceuticals is [Ga]Ga-PSMA-11. Herein, we summarize the preclinical development and the clinical applications of [Ga]Ga-PSMA-11 and present side-by-side comparisons with other radiopharmaceuticals or imaging modalities, in order to assist imagers and clinicians in recommending, performing, and interpreting the results of [Ga]Ga-PSMA-11 PET scans in patients with prostate cancer.
前列腺特异性膜抗原(PSMA)成像已成为管理复发性前列腺癌患者的重要工具,而最常用的放射性药物之一是[镓]Ga-PSMA-11。在此,我们总结了[镓]Ga-PSMA-11的临床前开发和临床应用,并与其他放射性药物或成像方式进行了并列比较,以帮助影像科医生和临床医生在前列腺癌患者中推荐、进行和解释[镓]Ga-PSMA-11 PET扫描的结果。